Kai McGreevy is a Neurology physician affiliated with NeuroHealing Pharmaceuticals. OpenAlex indexes 22 publications with 599 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
559 W Twincourt Trl
Suite 607
St Augustine, FL 320958805
Telephone
904-230-3006Provider last certified this registry record 27 Feb 2021.
Industry payments
62 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year202511 payments
- Boston Scientific CorporationProgram year202518 payments
- Curonix LLCProgram year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
77.3%Corticosteroid77.3%Triamcinolone acetonide100%Methylprednisolone0%Part D + Part B≥362 patientsMusculoskeletal
14.3%Neuromuscular Blocker13.2%Onabotulinumtoxina100%Botox0%Part D + Part B<11 patientsMuscle Relaxant0.6%Cyclobenzaprine Hcl57%Methocarbamol40%Carisoprodol4%Part D<11 patients+ 3 more classes in this area
Nervous system
6.6%Opioid Agonist2.3%Oxycodone-Acetaminophen33%Oxycodone Hcl27%Tramadol Hcl21%Morphine Sulfate Er7%Fentanyl6%Hydromorphone Hcl3%Methadone Hcl2%Morphine Sulfate1%Part D<11 patientsGabapentinoids1.4%Gabapentin72%Pregabalin28%Part D≥139 patients+ 20 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ID# 1899964 Autonomic Nervous System Changes Following Spinal Cord Stimulation
Neuromodulation Technology at the Neural Interface
2025 - ID# 1901238 Physiologic Biomarkers for Chronic Pain - A Retrospective Study on Changes Following Spinal Cord Stimulation
Neuromodulation Technology at the Neural Interface
2025 - ID# 1894859 Microcirculation Changes Following Spinal Cord Stimulation
Neuromodulation Technology at the Neural Interface
2025 - ID# 1880071 Quantitative Electroencephalographic Changes Following Spinal Cord Stimulation
Neuromodulation Technology at the Neural Interface
2025 - ID# 1880167 Cognitive Changes Following Spinal Cord Stimulation
Neuromodulation Technology at the Neural Interface
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”